|
|
|
| Network meta-analysis of Osimertinib combination therapy for advanced non-small cell lung cancer |
| SANG Bulin1 HUANG Huiyuan2 WANG Xurao2 DONG Lixian2 XU Rong2 FAN Yuxin2 FENG Jin2 HE Jianchang2 |
1.School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Yunnan Province, Kunming 650500, China;
2.Clinical Pharmacology Research Center, Yunnan Provincial Hospital of Traditional Chinese Medicine, Yunnan Province, Kunming 650103, China |
|
|
|
|
Abstract Objective To evaluate the efficacy of Osimertinib (OSI) combination therapy in the treatment of advanced non-small cell lung cancer (NSCLC) by network meta-analysis. Methods Cochrane Library, PubMed, CNKI, Wanfang Data, and China Biology Medicine Disc were searched for randomized controlled trials on OSI combination therapy of advanced non-small cell lung cancer from the inception to September 2022. Information extraction and quality evaluation were performed on the included studies. Stata 15.0 and Review Manager 5.3 software were used for network meta-analysis. Results A total of 25 literatures were included, involving 2 374 patients. The intervention measures included OSI alone and OSI combined with first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), standard treatment (first-generation EGFR-TKI + platinum), Shenyi Capsules, Valmenin Capsules, Yiqi Yangyin Prescription, Bevacizumab, and chemotherapy, and the control measures included OSI, first-generation EGFR-TKI, standard treatment, chemotherapy, and chemotherapy combined with Bevacizumab. The top three interventions in the surface under the cumulative ranking curve (SUCRA) of objective response rate were OSI + Yiqi Yangyin Prescription (85.0%), OSI + Beizumab (72.4%), OSI+ standard treatment (71.6%), and OSI+ Shengyi Capsules (71.6%). The top three interventions in SUCRA in disease control rate were OSI+ Bevacizumab (88.7%), OSI+ Valmenin Capsules (86.2%), and OSI+ Yiqi Yangyin Prescription (76.0%). Conclusion In the treatment of advanced non-small cell lung cancer, the combination of OSI, Yiqi Yangyin Prescription, and Bevacizumab may be the best choice in the future.
|
|
|
|
|
|
[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Chen P，Liu Y，Wen Y，et al. Non-small cell lung cancer in China [J].Cancer Commun（Lond），2022，42（10）：937-970.
[3] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates ofincidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[4] Greig SL. Osimertinib：First Global Approval [J]. Drugs，2016， 76（2）：263-273.
[5] 米雪，苏雪龙，孙维红，等.奥希替尼治疗晚期非小细胞肺癌的药物经济学系统评价[J].中国药房，2021，32（6）：713-719.
[6] Bertoli E，De Carlo E，Del Conte A，et al. Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer：How Do We Overcome It？[J]. Int J Mol Sci，2022，23（13）：6936.
[7] Higgins JPT，Thomas J，Chandler J，et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 [EB/OL]. （2021-02-01）[2023-02-04]. http：//www.training.cochrane.org/ han- dbook.
[8] Soo RA，Han JY，Dafni U，et al. A randomised phase Ⅱ study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations：the European Thoracic Oncology Platform（ETOP 10-16）BOOSTER trial [J]. Ann Oncol，2022，33（2）：181-192.
[9] 田永巍.常规放疗联合奥希替尼治疗晚期非小细胞肺癌的临床价值研究[J].数理医药学杂志，2022，35（2）：206- 208.
[10] 吴皓，李萍.奥希替尼联合放化疗治疗晚期非小细胞肺癌患者的临床疗效及安全性分析[J].中国肿瘤临床与康复，2020，27（4）：400-403.
[11] 苏大伟，郑鑫宾，韩瑜鹏，等.贝伐珠单抗联合奥希替尼治疗EGFR-T790M突变的晚期非小细胞肺癌患者的临床效果[J].河南医学研究，2022，31（7）：1305-1309.
[12] 周盈盈，田菲，张桂星，等.威麦宁胶囊联合奥希替尼治疗EGFR T790M突变晚期肺腺癌的临床疗效[J].江苏医药，2022，48（4）：371-374.
[13] 王立，姜忠于，胡春秀，等.奥希替尼联合培美曲塞、顺铂方案化疗对晚期非小细胞肺癌患者无进展生存期及总生存期的影响[J].广东医学，2022，43（4）：412-415.
[14] 张冉冉，朱竹.观察奥希替尼治疗晚期非小细胞肺癌患者的治疗价值[J].糖尿病天地，2022，19（8）：94-95.
[15] Tanaka K，Asahina H，Kishimoto J，et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR（T790M）-associated resistance to initial EGFR inhibitor treatment：An open-label，randomised phase 2 clinical trial [J]. Eur J Cancer，2021，149：14-22.
[16] 陈振洋，李欣，贾玉凤，等.奥希替尼辅助DP方案治疗晚期非小细胞肺癌的疗效及其对血清hCAP18及Pokemon表达的影响[J].药物评价研究，2021，44（9）：1927-1933.
[17] 田慧娟，杜燕子.放化疗联合奥希替尼治疗晚期非小细胞肺癌的疗效观察[J].中国肿瘤临床与康复，2021，28（10）：1220-1223.
[18] 蒋轶，叶韬. 奥希替尼联合放化疗对晚期NSCLC患者血清肿瘤因子水平的影响[J].医学理论与实践，2021，34（21）：3738-3740.
[19] 李光斌，丁岩，孙红辉.奥希替尼联合TC方案治疗转移性非小细胞肺癌的疗效及安全性分析[J].实用癌症杂志，2021，36（11）：1884-1886，1897.
[20] 韩笑.奥希替尼治疗晚期非小细胞肺癌的疗效观察[J].中国现代药物应用，2021，15（8）：169-171.
[21] 于盼，刘洋，郑彩霞，等.益气养阴方联合化疗、甲磺酸奥希替尼片治疗非小细胞肺癌脑转移的临床疗效观察[J].河北中医，2021，43（1）：87-91.
[22] 李新莉.甲磺酸奥希替尼片联合PC化疗方案在晚期非小细胞肺癌治疗中的效果[J].航空航天医学杂志，2020， 31（12）：1483-1484.
[23] Toi Y，Hayashi H，Fujimoto D，et al. A randomized phase Ⅱ study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation（West Japan Oncology Group 8715L）[J]. Ann Oncol，2020，31：S813-S814.
[24] 江冠铭，谭钦全，刘淳，等.人参皂苷Rg3联合奥希替尼治疗一代EGFR-TKI耐药型晚期非小细胞肺癌的疗效及安全性[J].新医学，2019，50（7）：505-509.
[25] 韩丽萍.奥希替尼治疗EGFR T790M阳性非小细胞肺癌的临床效果研究[J].家庭医药，2019（11）：147.
[26] 燕丽香，孙红梅，李源，等.奥希替尼治疗晚期T790M突变肺腺癌患者疗效分析[J].中华实用诊断与治疗杂志，2019，33（4）：395-397.
[27] 朱朝勇，曹淑琴.奥希替尼联合厄洛替尼治疗EGFR- T790M突变的非小细胞肺癌的疗效[J].实用癌症杂志，2019，34（8）：1328-1330，1361.
[28] Nie K，Zhang Z，Zhang C，et al. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer [J]. Lung Cancer，2018， 121：5-11.
[29] Soria JC，Ohe Y，Vansteenkiste J，et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J]. N Engl J Med，2018，378（2）：113-125.
[30] 姚逸临，李和根，陈智伟，等.益气养阴解毒方内服外治对非小细胞肺癌患者靶向治疗相关皮肤毒性反应及皮肤病生活质量指数的影响[J].中国医药，2022，17（6）：836-840.
[31] 袁建平，吕艳，李玲瑞，等.复方威麦宁胶囊长期毒理实验安全性评价[J].中华中医药学刊，2020，38（8）：233- 236.
[32] 姜振蕊，李泉星，曲霞.参一胶囊联合吉非替尼对晚期非小细胞肺癌患者外周血清基质金属蛋白酶-9的影响[J].世界中医药，2018，13（8）：1883-1886，1890.
[33] Zhou Y，He M，Li R，et al. The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small- Cell Lung Cancer：A Meta-Analysis of Randomized Controlled Trials [J]. Biomed Res Int，2021，2021：5537899.
[34] Deng WS，Wang K，Jiang Y，et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer：a systematic review and meta-analysis of randomised controlled trials [J]. BMJ Open，2022，12（8）：e062036. |
|
|
|
